Launched in Jan-2016, Paragate Medical is an Israeli innovative startup, aiming to revolutionize the heart failure epidemic management by introducing the first implantable medical device that actively and continuously prevents fluid overload in congestive heart failure patients. The device absorbs systemic extracellular fluid and drains it to the urinary system in a safe and controlled manner.
With its encouraging pre-clinical results and strong IP coverage, the company is currently looking to complete series A to support European based operation towards FIM trials.
Paragate's IPU is a minimally invasive, fully implantable device that continuously and actively drains excess systemic extracellular fluid, maintaining fluid overloaded heart failure patients in normal volumes and reducing the need for repeated hospitalizations for acute treatments.
CEO and Co-founder of Paragate Medical. Over 11 years’ experience in cardiovascular devices field in R&D engineering and management positions, from which 7 with Enopace Biomedical, pioneering the conceptualization and development of intravascular neurostimulation device. Holds B.Sc. in BME from the Technion, resulting in a spinoff startup (Pneumedicare) and an M.Sc. in BME from the Technion-IIT, awarding him with ISHR young investigator award for the research in cardiac resynchronization therapy.
David Harel
Presentation Time and Location
on 25th, during Rising Israeli Stars Session (from 15.40 to 16.15)
CytoReason is a big-data analytics company specializing in immunotherapy using its proprietary Cell-Centered Model. The proprietary machine-learning engine enhances its performance with each new dataset introduced, leveraging hundreds of published and unpublished immunotherapy datasets. Its prior knowledge allows for ever-improving accuracy, translating high-resolution measurements to specific immune-cellular interactions that extend beyond the data provided by the customer and can be translated to valuable IP. CytoReason’s technology has yielded 2 pending patents, 7 scientific collaborations and 12 peer reviewed publications
Our technology integrates different genomic and proteomic measurements with clinical data and predicts cellular immunological pathways.
The proprietary machine-learning engine enhances its performance with each new dataset introduced, leveraging hundreds of published and unpublished immunotherapy trials. Its prior knowledge allows for ever-improving accuracy, translating high-resolution measurements to specific immune-cellular interactions. The system generates immune interaction networks that extend beyond the data provided by the customer.
CytoReason is generating valuable IP and Know-How for biotech and pharmaceutical companies, universities and research institutions throughout their basic research, drug development, and clinical trials.
Investment and Licensing (In/Out) Opportunity 1: Name
on 27th, during Rising Biotech Stars Session (from 14.00 to 16.00)
Company Profile
Dolopharm is a drug development company from Charité, Berlin, with a focus on GPCR-targeted therapies. Our first pipeline candidate NFEPP for the treatment of severe acute and chronic pain has shown impressive performance in several pre-clinical trial models. In contrast to standard medications, such as opioids, NFEPP avoids drug addiction, respiratory depression, constipation and other known side effects thus representing a potential breakthrough medication for many pain related indications.
Investment and Licensing (In/Out) Opportunity 1: Name
NFEPP
Opportunity 1: Description
We are currently looking for investors to finance our clinical phase I studies in post-operative pain treatment after knee surgery. So, feel free to talk to us and find out, how to join this outstanding investment opportunity.
on 27th, during Rising Biotech Stars Session (from 14.00 to 16.00)
Company Profile
Juvabis is a recent Universität Zürich spin-off with a strong ETH-UZH IP portfolio in the field of anti-infective therapeutics. Juvabis is pre-seed stage currently operating out of UZH premises, about to enter the CTI coaching programme and bound to attract series A funding by the end of this year.
Albeit being a young startup company, our preclinical portfolio of leads has already been quite successful with the first candidate bound to enter non-clinical GLP tox in October 2017, thanks to an accelerator-type of partnership with the IMI ND4BB programme (http://nd4bb-enable.eu).
on 27th, during Rising Biotech Stars Session (from 14.00 to 16.00)
Company Profile
Junction Therapeutics, a clinical stage biotech developing siRNA technology for the safe controlled modulation of blood brain barrier (BBB) permeability. This will revolutionise the treatment of neurological conditions by selectively allowing small molecules to enter the brain as treatment as well as allowing pathological molecules to be removed. The BBB expresses high levels of tight-junction proteins, claudin-5 and occludin to prevent unwanted entry of solutes. Administration of siRNA complexes targeting claudin-5 (JT-01) and occludin + claudin-5 (JT-02) selectively and reversibly loosens the tight junction barrier component, this therapy renders the BBB reversibly permeable to compounds up to 10 kD for up to 36 hours. At Junction, we have taken advantage of previous issues with siRNA technology as we need only 30% suppression and can be delivered by peripheral injection for BBB permeability. Our completed FDA-observed GLP primate studies shown Glioblastoma Multiforme as a disease model to demonstrate JT-01 as an effective BBB drug delivery platform and treatment of cerebral edema. Our JT-02 programme is shown promise halting neurological conditions and symptoms such as reducing Aβ1-40 levels and increase cognitive ability in Alzheimer’s Disease model over 12 months of treatment. Our treatments are safe and no significant toxicity has been found.
Responsive Web Design powered by 